# XNW5004

Source: https://onco.cc/drugs/xnw5004/  
OnCo record `xnw5004` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.

## Summary

XNW5004 is a small-molecule drug developed by Evopoint Biosciences. Its target is EZH2. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in follicular lymphoma and prostate cancer. The largest, NCT06702995, plans to enrol 307 participants with primary completion was scheduled for 2026-05-13 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: EZH2i
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: Small-molecule drug directed at EZH2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of XNW5004: https://clinicaltrials.gov/search?intr=XNW5004
- Sponsor page: https://www.evopointbio.com

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [EZH2](https://onco.cc/targets/ezh2/)
- companies: [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/)
- trials: [A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma](https://onco.cc/trials/nct06776952/), [Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma](https://onco.cc/trials/nct07730515/), [Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma](https://onco.cc/trials/nct07545603/), [Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct06702995/)

---
JSON: https://onco.cc/api/v1/entities/xnw5004.json